Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 8/20 | 0.38 |
| ▸ | FGF1 | P05230 | 7/20 | 0.38 |
| ▸ | FGF2 | P09038 | 7/20 | 0.38 |
| ▸ | VEGFA | P15692 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901508 | 1.00 | HPSE (0.38) | HPSEFGF1FGF2VEGFACA12 | |
| SCHEMBL13248408 | 0.91 | HPSE (0.34) | HPSEFGF1FGF2VEGFACA1 | |
| SCHEMBL12479738 | 0.86 | HPSE (0.41) | HPSEFGF1FGF2VEGFACA12 | |
| SCHEMBL13272797 | 0.86 | HPSE (0.41) | HPSEFGF1FGF2VEGFACA12 | |
| SCHEMBL18513197 | 0.85 | HPSE (0.39) | HPSEFGF1FGF2VEGFACA12 | |
| SCHEMBL6923504 | 0.84 | FGF1 (0.44) | HPSEFGF1FGF2VEGFACA1 | |
| SCHEMBL13057268 | 0.84 | FGF1 (0.44) | HPSEFGF1FGF2VEGFACA1 | |
| SCHEMBL2175355 | 0.84 | FGF1 (0.44) | HPSEFGF1FGF2VEGFACA1 | |
| SCHEMBL6929305 | 0.84 | FGF1 (0.44) | HPSEFGF1FGF2VEGFACA1 | |
| SCHEMBL12406775 | 0.84 | BCHE (0.36) | HPSEFGF1FGF2VEGFACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973145-B2 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2130834-A1 | NOVEL SULFONATED SUGAR DERIVATIVE, AND USE THEREOF FOR MEDICINAL AGENT | Toyo Suisan Kaisha, Ltd. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | HPSE 995/4885FGF1 1431/4885FGF2 955/4885 |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | HPSE 995/4885FGF1 1431/4885FGF2 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.